About Us

Advancing early detection. Simplifying healthcare. Improving outcomes.

Seeing health,
not just vision

The eye offers a unique, non-invasive window into human health. A simple retinal examination can reveal early indicators of chronic eye disease and systemic conditions such as cardiovascular, kidney, liver, and neurological disorders, often long before symptoms appear.

Bringing intelligence
to the point of care  

Remidio brings clinically validated intelligence directly to the point of care. Our retinal imaging platforms combine advanced optics with on-the-edge AI to enable early detection and continuous monitoring of disease, delivering fast, reliable results without dependence on cloud connectivity and making them practical in real-world clinical settings.

From preventing blindness
to protecting long-term health

Preventing avoidable blindness remains central to our work. At the same time, we are expanding the role of eye care in protecting long-term health by shifting care from late-stage treatment to proactive, preventive management.

Designed for real-world care. Built to scale.

We design simple, regulatory-approved devices that perform reliably across tertiary hospitals, specialist practices, primary care, outreach programs, and last-mile settings, without compromising clinical quality.

Clinically proven.
Globally trusted.

As a pioneer in AI-driven eye care, Remidio was the first company to receive CDSCO approval in India for adaptive ophthalmic AI, alongside CE marking under EU-MDR. Our CE-marked and FDA 510(k)-registered devices have been used to screen more than 16 million people across 55 countries.

A simple idea.
A far-reaching impact.

Founded over 15 years ago with a vision to decentralise eye testing through simple, accessible technology, Remidio continues to focus on simplifying care, expanding access, and enabling better health outcomes for millions.